行情

PRTK

PRTK

Paratek生物制药
NASDAQ

实时行情|Nasdaq Last Sale

3.120
+0.010
+0.32%
盘后: 3.120 0 0.00% 16:00 12/11 EST
开盘
3.120
昨收
3.110
最高
3.180
最低
3.100
成交量
25.44万
成交额
--
52周最高
7.39
52周最低
2.660
市值
1.03亿
市盈率(TTM)
-0.8137
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PRTK 新闻

  • Seth Klarman Pares Paratek Pharmaceuticals Stake
  • GuruFocus.com.1天前
  • 12 Biotech Stocks Primed For A Short Squeeze
  • Benzinga.5天前
  • 12 Biotech Stocks Primed For A Short Squeeze
  • Benzinga.5天前
  • 意大利最大商业银行拟裁员8000人
  • 新浪财经.12/03 07:12

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

PRTK 简况

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.
展开

Webull提供Paratek Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。